Laddar populära aktier...
Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Buspiron tablets in Sweden.
Newbury Pharmaceuticals year-end report September 2023 – August 2024
Newbury has agreed to a 12-month extension of the loan agreement announced on the 18th of September, 2023.
Newbury Pharmaceuticals AB is pleased to announce higher than expected sales growth in Quarter 4 (June-Aug 2024) reaching sales of approxima...
Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Varenicline Newbury in Sweden.
Newbury has through one of its partners initiated a DCP filing for Teduglutide on Day-1 following the expiry of Data Exclusivity.
Extraordinary general meeting in Newbury Pharmaceuticals AB (publ) (the ”Company”) was held on 31 July 2024.
Swedish version follow after the English version.
Newbury Pharmaceuticals interim report September 2023 – May 2024
Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Liraglutide pre-filled pen in Denmark as the f...
Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Dalbavancin 500mg Powder for...
Newbury Pharmaceuticals interim report September 2023 – February 2024
Newbury Pharmaceuticals AB (“Newbury” or the “Company”) carries out a directed share issue of approximately 4.
Newbury Pharmaceuticals is delighted to announce the receipt of a sales order, scheduled for delivery in May 2024, from an customer located ...
Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Nintedanib Newbury 100 & 150 mg soft capsules tablets in ...
The annual general meeting of Newbury Pharmaceuticals was held on Wednesday, 10 January 2024.
Newbury Pharmaceuticals interim report September 2023 – November 2023
Newbury Pharmaceuticals AB has published its annual report for the 2022/2023 financial year.
Notice of annual general meeting
Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Melatonin Extended Release 2...
Newbury Pharmaceuticals year-end report September 2022 – August 2023
Newbury has signed a contract with Amarox Limited to represent and distribute their products in Sweden and Denmark.
Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Levodopa/Benserazide tablets...
Newbury has secured immediate funding represented by a loan of 15 MSEK from independent private investors.
A new strategic partnership with a global pharmaceutical company underpins the strategic ambition of being a local champion and provides New...
Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Desmopressin Newbury 60, 120 & 240 mcg sublingual tablets...
Newbury Pharmaceuticals AB today announces its five-year goals for the business.
Newbury Pharmaceuticals interim report September 2022 – May 2023
Newbury Pharmaceuticals has previously announced that the interim report for the period September 2022 – May 2023 will be published on July ...
On June 1st at 10:00 CEO, Lars Minor will discuss the latest developments in Newbury Pharmaceuticals at Redeye Growth Day 2023.
Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Pirfenidone Newbury 267 & 801 mg film-coated tablets in N...
Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Solifenacin/Tamsulosin Newbury 6 mg/0,4 mg modified relea...
Newbury Pharmaceuticals interim report September 2022 – February 2023
Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Lapatinib Newbury 250 mg film-coated tablets in Sweden as...
Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Dimethyl Fumarate Newbury 120 & 240 mg hard capsule in Sw...
Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Buspirone tablets.
The annual general meeting of Newbury Pharmaceuticals was held on Wednesday, 11 January 2023.
Newbury Pharmaceuticals interim report September 2022 – November 2022
Newbury Pharmaceuticals has received orders for international markets covering shipments during 2023 totalling a value of app.
Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Fampridine Newbury 10 mg prolonged-release tablets in Swe...
Newbury Pharmaceuticals AB has published its annual report for the 2021/2022 financial year.
Following the recent publication of its analysis of Newbury Pharmaceuticals, Redeye will host two events where Newbury Pharmaceuticals, CEO,...
Newbury Pharmaceuticals is pleased to announce the expansion of its portfolio with Daptomycin and Linezolid with already granted Marketing A...
Lars Minor, CEO, Newbury Pharmaceuticals presents at Redeye Life Science Day 2022.
Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Teriflunomide Newbury 14 mg film-coated divisible tablets...
Newbury Pharmaceuticals year-end report September 2021 – August 2022
Newbury Pharmaceuticals management has purchased shares in the company
Newbury Pharmaceuticals engages Pareto Securities to reduce spread in share price
Newbury Pharmaceuticals is pleased to announce the appointment of Mrs.
“Besides sales uptake in both Norway and Sweden, we continue to invest in new license opportunities as well as ongoing regulatory filings of...
Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Teriparatide injection pre-f...
Newbury Pharmaceuticals is strengthening its portfolio with two new products
“It has been another strong Quarter with significant milestones.
Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Sunitinib Newbury in Denmark as the first country in a Sc...
Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Lenalidomide Newbury in Sweden as the first country in a ...
Newbury Pharmaceuticals AB has successfully entered the Swedish and Norwegian market by making its first product available to patients and p...
Newbury Pharmaceuticals’ CEO has joined an interview with Västra Hamnen Corporate Finance where the topic was Newbury’s choice of business f...
The Board of Directors of Newbury Pharmaceuticals AB (“Newbury” or “the Company”) decided on January 10th, 2022, with the support of the aut...
Newbury Pharmaceuticals interim report September 2021 – November 2021
Newbury Pharmaceuticals is pleased to announce the agreement of an exclusive license to commercialize its own brand of Teduglutide 5mg pre-f...
Newbury Pharmaceuticals is pleased to announce the successful enlargement of the oncology portfolio with the addition of Lapatinib.
Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with additional seven (7) oncology products; Nint...
